Arletta’s Lybrido Shows Strong Phase II Signal in Female Sexual Arousal Disorder

A small study. A big signal. Arletta Pharma Solutions has reported positive Phase II results for its lead asset Lybrido, targeting Female Sexual Interest/Arousal Disorder (FSIAD), one of the most under-addressed areas in women’s health.

The headline: Objective, measurable improvement in physiological arousal. That’s rare in this space.

Why This Matters?

FSIAD isn’t niche.

• ~8% of adult women globally are affected
• That’s ~250 million women
• Limited approved, effective treatments

Most therapies rely heavily on subjective endpoints. This study changes that.

The Study at a Glance

• Phase II, randomized, open-label
• 16 premenopausal women
• Conducted at Chaim Sheba Medical Center
• Led by Cobi Reisman

What Was Tested?

Two dose combinations of Lybrido:

• Testosterone + Sildenafil (standard dose)
• Testosterone + Sildenafil (high dose: 1.0 mg / 100 mg)

Primary Endpoint

• Change in Peak Systolic Velocity (PSV)
• Measured via Clitoral Doppler Duplex Ultrasound (CDU)

In simple terms: Blood flow = proxy for genital arousal

The Results: Clear Physiological Signal

1. First-Time Biomarker Validation

• First objective CDU data for high-dose combination
• Moves beyond self-reported outcomes

2. Strong Efficacy

• >60% improvement in clitoral blood flow (PSV)
• Seen across both dose groups

3. Statistical Significance

• High-dose arm achieved p = 0.008
• Impressive given small sample size (n=16)

4. Hospital-Level Relevance

• Demonstrates real physiological response, not just perception

Mechanism: Why This Works?

Lybrido uses a dual-action approach:

Central + Peripheral Targeting

• Testosterone (sublingual): Boosts sexual motivation (brain)
• Sildenafil (oral, PDE5 inhibitor): Increases genital blood flow (body)

Together, this aligns desire + arousal timing

Formulation Innovation

This isn’t just a combo pill. Lybrido uses a:

• Dual-route delivery system
• Delayed-immediate release mechanism

What that achieves:

• Testosterone acts first (motivation window)
• Sildenafil peaks later (arousal response)

Effects last 3–6 hours. Designed for on-demand use

Why Combination Therapy Matters?

Earlier research already hinted at this. Combination therapy:

• Outperforms monotherapy
• Enhances genital blood flow significantly
• Requires both central + peripheral activation

This study reinforces that thesis—with objective data.

Development Strategy: What’s Next

Arletta is moving forward on two tracks:

1. Pivotal Study (Europe)

• Larger, registration-focused trial
• Dose confirmed from current study

2. Additional Phase II (US)

• Focus on high-dose combination
• Goal: refine efficacy + safety profile

Execution may be:

• Sequential
• Or partially overlapping

The Bigger Picture: An Unmet Need

FSIAD is defined in Diagnostic and Statistical Manual of Mental Disorders (DSM-5) as:

• Reduced sexual interest and/or arousal
• Persistent for ≥6 months
• Causes clinically significant distress

It combines:

• Hypoactive Sexual Desire Disorder (HSDD)
• Female Sexual Arousal Disorder

Despite prevalence, treatment innovation has lagged.

What Makes Lybrido Different?

Most existing options:

• Target either desire OR arousal
• Not both

Lybrido:

• Targets both simultaneously
• Uses on-demand dosing
• Anchored in physiology, not just perception

Final Take

Let’s be clear. This is:

• Small sample size (n=16)
• Early-stage signal

But also:

• Objective biomarker validation
• Statistically significant response
• Mechanistically sound approach

That combination is hard to ignore. If larger trials replicate this: Lybrido could become one of the first truly mechanism-driven therapies in female sexual dysfunction. The risk now shifts from “Does it work?” To: “Can it scale clinically?”